Rosa & Co. to Present Research Results with 5 Posters and a Tutorial at the 2015 American Conference on Pharmacometrics

SAN CARLOS, Calif., Sept. 23, 2015 /PRNewswire/-- Rosa & Co. LLC, the leading commercial drug development advisory firm with expertise in Quantitative Systems Pharmacology (QSP)/PhysioPD™, today announced five posters and a tutorial that will be presented during the sixth American Conference on Pharmacometrics (ACoP6) in Crystal City, VA, October 4-7, 2015.  

Logo - http://photos.prnewswire.com/prnh/20150922/269512LOGO

The poster presentations will describe research and a range of results including the application of PhysioPD Platforms to clinical trial design and translational research. The posters will be presented with Sanofi, Bristol Myers Squibb, Stiefel, (a GSK company) and by Rosa & Co. The MathWorks, Inc. tutorial uses a Rheumatoid Arthritis PhysioPD Platform developed by Rosa to illustrate the use of SimBiology and MATLAB to streamline QSP workflows. The presentations will be:

Enhancing the Utility of Systems Pharmacology Modeling in Pharmaceutical R&D: Lessons from the Development of a PCSK9 Inhibitor Model: Presented by Sanofi

Development of a Quantitative Systems Pharmacology (QSP) Platform to Support Translational Research and Clinical Development in Immuno-Oncology: Presented by Bristol Myers Squibb

Development of a Quantitative Systems Pharmacology (QSP) Model of Psoriasis: Overview and Challenges: Presented by Stiefel

Enabling and streamlining QSP workflows with SimBiology and MATLAB: Presented by MathWorks and Rosa & Co.

A Quantitative Systems Pharmacology (QSP) Platform to Investigate the Impact of Cholesterol Lowering Therapies Insights for the Clinical Application of PCSK9 Inhibitors: Presented by Rosa & Co.

Model Qualification Approaches for Quantitative Systems Pharmacology (QSP) and Mechanistic Physiological Models: Presented by Rosa & Co. 

Posters will be available on the Rosa & Co website at www.rosaandco.com/publications.html after the conclusion of the ACoP6 meeting. 

"We are pleased to share the results of our innovative research and that of our clients, and are honored that our submitted presentations were accepted for inclusion in the ACoP6 2015 meeting."

                                                                     - Dr. Mike Reed, Rosa & Co. Chief Scientist

About Rosa 
Rosa supports clients with their critical decisions – from preclinical through clinical development – by creating and using customized PhysioPD™ Research Platforms that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Thereby reducing R&D related challenges in translating targets to outcomes. Rosa's clients are involved in Platform creation, testing, and biological simulation research. Clients retain the Platform as a program asset to support decisions and future research. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to accelerate drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area experience, including metabolic diseases, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system disorders, dermatology, and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html.

Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

Media Contact:
Stephanie Sherman
425-591-5738
Email

SOURCE Rosa & Co.